Lupin Secures US FDA Approval for Generic Diazepam Injection

MUMBAI & NAPLES, Fla. — Global pharmaceutical company Lupin Limited announced on July 28, 2026, that it has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), packaged in single-dose prefilled syringes.

The regulatory clearance under the Federal Food, Drug, and Cosmetic Act enables the Mumbai-headquartered drugmaker to market its generic formulation as bioequivalent to Hoffmann-La Roche’s reference listed drug, Valium Injection. The development expands Lupin’s central nervous system and injectable product portfolios in the United States, addressing an estimated $77.9 million annual market.

Strategic Market Impact and Portfolio Expansion

The newly approved generic formulation is indicated for managing anxiety disorders and providing short-term relief from anxiety symptoms. According to IQVIA Moving Annual Total (MAT) data through May 2026, the U.S. market for Diazepam Injection USP in prefilled syringes generated approximately $77.9 million in annual sales.

Lupin U.S. FDA Approval Overview:
├── Product: Diazepam Injection USP, 10 mg/2 mL (5 mg/mL)
├── Delivery Format: Single-Dose Prefilled Syringes
├── Reference Listed Drug (RLD): Valium® Injection (Hoffmann-La Roche, Inc.)
├── Targeted Indication: Management of Anxiety Disorders
└── Annual U.S. Market Value: $77.9 Million (IQVIA MAT May 2026)

The clearance highlights Lupin's ongoing strategic transition toward high-barrier complex generics and specialized injectable delivery formats. Prefilled syringes represent a value-added delivery system compared to standard oral formulations, helping mitigate traditional pricing pressure in generic pharmaceuticals.

Regulatory and Technical Details

The FDA clearance certifies that Lupin’s single-dose prefilled syringe formulation demonstrates bioequivalence and therapeutic equivalence to the brand-name baseline drug, Valium.

The approval process required meeting standardized purity, efficacy, and quality criteria for parenteral solutions under U.S. Pharmacopeia (USP) guidelines. Manufacturing operations and delivery system compliance align with strict U.S. FDA Current Good Manufacturing Practice (cGMP) regulations.

Official Company Disclosures

In a regulatory statement filed on July 28, 2026, Lupin confirmed the receipt of the approval notification and outlined the addressable U.S. commercial market size.

"Lupin Limited today announced that it has received approval under the Federal Food, Drug, and Cosmetic Act for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes," stated company officials in a press announcement issued simultaneously from Mumbai and Naples, Florida.

Why It Matters

Securing U.S. approval for complex injectable formats allows generic drugmakers to build reliable revenue streams in specialized market segments. For healthcare facilities and providers across the United States, the availability of an FDA-approved generic prefilled syringe offers an additional supply source for critical central nervous system medications, helping prevent potential drug shortages.

Key Facts at a Glance

• Approved Formulation: Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes.

• Reference Listed Drug: Valium® Injection (Hoffmann-La Roche, Inc.).

• Therapeutic Category: Central Nervous System / Anxiolytic.

• Addressable Market Size: $77.9 million annually in the U.S. (IQVIA MAT May 2026).

• Announcement Date: July 28, 2026.

Frequently Asked Questions (FAQ)

What is Diazepam Injection USP indicated for?

Diazepam Injection USP is approved for managing anxiety disorders and providing short-term relief from symptoms of anxiety.

What is the brand name equivalent for this generic drug?

Lupin's generic formulation is bioequivalent to Valium® Injection (10 mg/2 mL) manufactured by Hoffmann-La Roche, Inc.

How large is the market for generic Diazepam prefilled syringes in the U.S.?

According to IQVIA data for MAT May 2026, single-dose prefilled syringes of Diazepam Injection recorded estimated U.S. annual sales of $77.9 million.

Sources: Lupin Limited Corporate Press Release - PR Newswire. Company Disclosure to Stock Exchanges